OncoCyte, BioRad to partner on global launch of GraftAssure assay

The company states: “Oncocyte (OCX) announced a partnership agreement with Bio-Rad Laboratories (BIO) for the commercialization of its research use only GraftAssure assay, powered by Droplet Digital PCR. The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more broadly in the second half of the year. As part of the agreement, Bio-Rad and Oncocyte will co-market the assay inside the US and Germany, with Oncocyte acting as commercial lead. Outside these countries Bio-Rad has been granted exclusive global distribution and commercial rights.”